ISIN | LU1587985067 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Bellevue Asia Pacific Healthcare I2 CHF |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland |
Waystone Fund Services (Switzerland) SA Lausanne Phone: 0041213111781 |
Distributor(s) |
Bank am Bellevue AG Küsnacht Phone: +41 44 267 67 67 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The sub-fund is an equity fund. The investment objective of the sub-fund is to achieve long-term capital growth by investing at least two thirds of the net assets of the fund in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of the Asia-Pacific region. The universe for companies is determined cumulatively as follows: Shares of companies that have their registered office or carry out the majority of their economic activity in the healthcare sector in the Asia-Pacific region. These include companies operating in such areas as generics, medtech, biotech, pharma and health services which are involved in the development, manufacture or sale of products and services. Listed on a recognised stock market or, in the case of an initial public offering, the company has applied for listing on the relevant exchange. |
Peculiarities |
Current Price * | 147.71 CHF | 05.09.2024 |
---|---|---|
Previous Price * | 148.83 CHF | 04.09.2024 |
52 Week High * | 152.35 CHF | 27.09.2023 |
52 Week Low * | 135.03 CHF | 05.08.2024 |
NAV * | 147.71 CHF | 05.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 123,640,481 | |
Unit/Share Assets *** | ||
Trading Information SIX |
YTD Performance | +3.53% |
29.12.2023 - 05.09.2024
29.12.2023 05.09.2024 |
---|---|---|
1 month | +9.39% |
05.08.2024 - 05.09.2024
05.08.2024 05.09.2024 |
3 months | +3.72% |
05.06.2024 - 05.09.2024
05.06.2024 05.09.2024 |
6 months | -0.33% |
05.03.2024 - 05.09.2024
05.03.2024 05.09.2024 |
1 year | -0.84% |
05.09.2023 - 05.09.2024
05.09.2023 05.09.2024 |
2 years | -15.17% |
05.09.2022 - 05.09.2024
05.09.2022 05.09.2024 |
3 years | -42.26% |
06.09.2021 - 05.09.2024
06.09.2021 05.09.2024 |
5 years | -44.60% |
15.06.2021 - 05.09.2024
15.06.2021 05.09.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Daiichi Sankyo Co Ltd | 10.21% | |
---|---|---|
Otsuka Holdings Co Ltd | 7.67% | |
CSL Ltd | 5.73% | |
Samsung BioLogics Co Ltd | 5.30% | |
Legend Biotech Corp ADR | 5.24% | |
Terumo Corp | 4.45% | |
Takeda Pharmaceutical Co Ltd | 4.45% | |
Olympus Corp | 4.29% | |
Celltrion Inc | 4.16% | |
Hoya Corp | 3.65% | |
Last data update | 31.07.2024 |
TER | 1.52% |
---|---|
TER date | 29.01.2021 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.48% |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |